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Abstract
Receptor tyrosine kinases and integrins play an essential role in tumor cell invasion and metastasis. We previously showed
that EGF and other growth factors induce human carcinoma cell invasion and metastasis mediated by integrin avb5 that is
prevented by Src blockade [1]. MUC1, a transmembrane glycoprotein, is expressed in most epithelial tumors as
a heterodimer consisting of an extracellular and a transmembrane subunit. The MUC1 cytoplasmic domain of the
transmembrane subunit (MUC1.CD) translocates to the nucleus where it promotes the transcription of a metastatic gene
signature associated with epithelial to mesenchymal transition. Here, we demonstrate a requirement for MUC1 in carcinoma
cell metastasis dependent on EGFR and Src without affecting primary tumor growth. EGF stimulates Src-dependent MUC1
cleavage and nuclear localization leading to the expression of genes linked to metastasis. Moreover, expression of MUC1.CD
results in its nuclear localization and is sufficient for transcription of the metastatic gene signature and tumor cell
metastasis. These results demonstrate that EGFR and Src activity contribute to carcinoma cell invasion and metastasis
mediated by integrin avb5 in part by promoting proteolytic cleavage of MUC1 and highlight the ability of MUC1.CD to
promote metastasis in a context-dependent manner. Our findings may have implications for the use and future design of
targeted therapies in cancers known to express EGFR, Src, or MUC1.
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Introduction
Epithelial tumor cell metastasis is the culmination of multiple
steps including remodeling and invasion of the extracellular matrix
[2]. Characterization of the molecular mechanisms coordinating
the migration machinery is critical to understanding tumor cell
dissemination to secondary sites. In this study, we have identified
signaling events that are coordinated by epidermal growth factor
(EGF) and a specific integrin to regulate the invasive behavior of
human carcinoma cells.
A growing body of literature has revealed that cooperative
signaling between receptor tyrosine kinases and integrins regulates
cell adhesion, migration, invasion, and survival [3]. In many
tumor types, including pancreatic cancer, members of the ErbB
family of receptor tyrosine kinases contribute to tumorigenesis and
metastasis [4]. We previously reported that integrin avb5, in the
absence of growth factor stimulation, is unable to form focal
adhesions and initiate cell migration/invasion [5]. However,
following EGF stimulation, cells expressing integrin avb5 gain the
ability to invade in vitro and metastasize in vivo [6,7] in a Src-
dependent manner [1]. In contrast, cell invasion mediated by b1
integrins occurs independent of EGF [6,7] and Src activity [1].
Understanding how EGFR and Src regulate avb5-mediated
tumor cell metastasis could lead to novel therapeutic strategies
to prevent the metastatic spread of human cancers.
The mucin-1 (MUC1) transmembrane glycoprotein undergoes
autocleavage within its SEA (sperm protein-enterokinase-agrin)
domain resulting in expression at the cell surface of a stable
heterodimer consisting of an extracellular and a transmembrane
subunit [8,9]. MUC1 interacts with ErbB family members
including EGFR and is a substrate for Src [10,11,12,13]. MUC1
is overexpressed and aberrantly glycosylated in human neoplasms,
particularly adenocarcinomas of the pancreas and breast, and its
expression correlates with metastasis [14,15]. Importantly, the role
of MUC1 in metastasis is associated with its intracellular domain,
which enters the nucleus and initiates the transcription of
a program of genes that modulate tumor metastasis [16,17,18,19].
Here, we show that EGF stimulation promotes MUC1 cleavage,
which is both necessary and sufficient to initiate tumor cell
metastasis but has no impact on primary tumor growth.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36753Importantly, EGF-induced MUC1 cleavage requires Src kinase
activity. These findings identify a pathway of EGF-dependent
metastasis that depends on Src-mediated MUC1 cleavage leading
to the expression of a metastatic gene signature. These studies may
explain in part how inhibitors of EGF or its receptor inhibit the
malignant properties of human tumors. Our findings also indicate
that Src may be a relevant downstream target for tumors that
depend on EGFR signaling and provide rationale for using
inhibitors of EGF or its receptors to suppress metastatic disease.
Results
MUC1 is required for EGF-induced migration and
metastasis
EGFR signaling promotes tumor cell metastasis [20,21,22].
Because MUC1 has been shown to interact with EGFR and has
been associated with metastasis [10,23], we assessed its re-
quirement in the well-characterized chick chorioallantoic mem-
brane (CAM) model of EGF-induced metastasis [24,25]. In this
model, FG human pancreatic carcinoma cells are stimulated with
a 15 minute treatment of EGF or vehicle in vitro and then
implanted on the CAM of 10 day-old chick embryos and allowed
to spontaneously metastasize to the lungs. After 10 days, primary
tumors were weighed and lung metastasis was assessed by Q-PCR.
EGF treatment significantly enhanced pulmonary metastasis of FG
cells expressing a control shRNA as expected (Figure 1a), but
shRNA-mediated knockdown of MUC1 expression selectively
blocked EGF-induced pulmonary metastasis without preventing
primary tumor growth (Figure 1a). These data implicate MUC1
as a key regulator of EGF-induced metastasis in this model.
Previous studies have demonstrated that EGF stimulates
carcinoma cell metastasis in vivo, and this is associated with the
induction of integrin avb5-mediated cell migration [1,7]. As such,
avb5-mediated carcinoma cell migration on a vitronectin substrate
in vitro may represent a surrogate assay for metastasis in vivo.T o
analyze the role of MUC1 in migration, FG cells subjected to
MUC1 knockdown were allowed to migrate on vitronectin or
collagen with or without a 15 minute pre-treatment with EGF.
EGF-induced migration on vitronectin was abolished by MUC1
knockdown (Figure 1b), supporting a role for MUC1 in the EGF-
dependent avb5-mediated cell migratory response. In contrast,
tumor cell migration on collagen was independent of EGF
stimulation and MUC1 since knockdown of MUC1 had no effect
on this migration response (Figure 1b). These findings suggest
that MUC1 is required for avb5-mediated EGF-induced carcino-
ma cell migration on vitronectin in vitro and spontaneous metastasis
in vivo.
EGF treatment promotes nuclear localization of MUC1
and expression of its target genes
The MUC1 cytoplasmic domain has been demonstrated to
translocate to the nucleus, where it promotes the transcription of
various genes linked to tumor cell invasion and metastasis
[17,19,26,27,28]. Therefore, we considered whether EGF stimu-
lation of FG cells could lead to nuclear translocation of MUC1. To
determine whether EGFR signaling induces nuclear translocation
of MUC1, we expressed full-length MUC1 (MUC1.FL) fused to
GFP and monitored the cells for MUC1 localization by
fluorescence microscopy. In the absence of EGF, MUC1.FL
localized to the plasma membrane. However, EGF treatment
significantly enhanced nuclear localization of MUC1 (Figure 2a).
To further evaluate the effect of EGF on MUC1 localization in
tumor cells, FG cells stimulated with EGF were probed for the
MUC1 by immunoblotting. EGF treatment enhanced the amount
of MUC1 in the nuclei of these cells within 30 minutes
(Figure 2b). Importantly, following EGF treatment, we detected
elevated transcript levels of several MUC1 target genes linked to
tumor cell invasion including TWIST, SNAI1, and SNAI2
(Figure 2c). Moreover, EGF-induced transcription was abolished
by MUC1 knockdown (Figure S1), supporting a critical role for
MUC1 in the EGF-dependent transcription of genes linked to
tumor cell invasion. Together, these results indicate that EGFR
signaling promotes translocation of MUC1 to the nucleus, where it
regulates transcription of genes linked to invasion and metastasis.
EGF treatment generates a MUC1 C-terminal fragment
that localizes to the nucleus and enhances expression of
MUC1 target genes
Recent studies have demonstrated that the MUC1 cytoplasmic
domain plays an important role in tumor cell invasion and
anchorage-independent growth [23,26,29]. Therefore, we consid-
ered whether EGF stimulation of FG cells could lead to cleavage of
MUC1. To determine whether EGFR signaling induces cleavage
of MUC1, whole cell lysates from FG cells treated with or without
a pulse of EGF were probed for the 15 kDa MUC1 cytoplasmic
domain by immunoblotting. Within 5 minutes of EGF treatment,
we observed increased levels of MUC1 cytoplasmic domain
(Figure 3a). To assess whether the 72 amino acid MUC1
cytoplasmic domain (MUC1.CD) would localize to the nucleus of
carcinoma cells in the absence of EGF, we expressed MUC1.CD
fused to GFP and monitored the cells for MUC1 localization. We
observed that MUC1.CD localized to the nucleus in the absence
of EGF (Figure 3b). Furthermore, expression of MUC1.CD
enhanced expression of MUC1 target genes linked to metastasis to
a similar degree as EGF treatment of FG cells (Figure 3c).
Together, these results indicate that EGFR signaling promotes
cleavage of MUC1 and translocation of the MUC1 cleavage
product to the nucleus, where it regulates transcription of
a metastatic gene signature.
The MUC1 cytoplasmic domain is required for EGF-
induced migration and sufficient for metastasis
We next asked whether this EGF-dependent MUC1 cleavage
product might play a role in EGF-dependent migration. To
determine whether the MUC1 cytoplasmic domain was necessary
for EGF-dependent migration, FG cells stably expressing MUC1
shRNA were transfected with shRNA-resistant full length MUC1
(MUC1.FL) or cytoplasmic domain-deleted MUC1 (MUC1.CT3)
and allowed to migrate with or without a 15 minute pre-treatment
with EGF. Whereas knockdown of MUC1 suppressed EGF-
mediated cell migration on vitronectin, this response was reversed
with MUC1.FL but not MUC1.CT3 (Figure 4a). In contrast,
expression of either MUC1.FL or MUC1.CT3 did not signifi-
cantly affect cell migration on collagen, consistent with our
findings that MUC1 is not required for EGF-independent cell
migration. We next asked whether the MUC1 cytoplasmic domain
(MUC1.CD) was sufficient to induce avb5-mediated migration on
vitronectin of FG cells in the absence of EGF. Interestingly,
expression of MUC1.CD in FG cells expressing endogenous
MUC1 was sufficient to promote migration on vitronectin without
EGF treatment but did not significantly affect migration on
collagen (Figure 4b).
We then considered whether the MUC1 cytoplasmic domain
might be sufficient for tumor cell metastasis. We tested whether
expression of MUC1.CD or MUC1.CT3 in FG cells could drive
spontaneous pulmonary metastasis in the chick CAM model.
Interestingly, expression of MUC1.CT3 significantly enhanced
EGF and Src Promote Metastasis by Cleavage of MUC1
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(Figure 4c). However, MUC1.CD enhanced spontaneous
pulmonary metastasis to an even greater degree (Figure 4c).
Importantly, expression of neither MUC1.CT3 nor MUC1.CD
significantly affected primary tumor mass (Figure 4c), consistent
with our finding that knockdown of MUC1 expression selectively
affected metastasis but not primary tumor growth (Figure 1a).
Together, these results demonstrate that the MUC1 intracellular
domain is both necessary for EGF-induced carcinoma cell
migration on vitronectin and sufficient to drive cell migration on
vitronectin and metastasis in the absence of EGF. In contrast, cell
migration on collagen is independent of both EGF and MUC1.
Src kinase activity is necessary and sufficient for cleavage
of MUC1, and MUC1 is required for Src-dependent
carcinoma cell migration
EGFR controls various signaling pathways including those of
the phosphoinositol-3-kinases, mitogen-activated protein kinases,
Janus kinases, and Src family kinases (SFKs) [4]. Importantly,
recent studies have demonstrated that activated EGFR recruits
and activates SFKs leading to enhanced tumor cell invasion and
metastasis [1,30,31,32]. Given that MUC1 is a substrate for Src
[11], we considered whether EGF-mediated cleavage of MUC1
was Src-dependent. FG cells were stimulated with a 15 minute
treatment of EGF or vehicle in the presence or absence of the Src
inhibitor bosutinib and analyzed for the presence of intact or
cleaved MUC1. EGF stimulation led to MUC1 cleavage, and this
was sensitive to Src inhibition (Figure 5a). We next asked
whether Src was sufficient to drive cleavage of MUC1 in FG cells.
Expression of constitutively active Src in FG cells readily promoted
MUC1 cleavage and nuclear localization (Figures 5b and 5c).
Together, these results demonstrate that Src kinase activity is both
required for MUC1 cleavage and sufficient for translocation of the
cleavage product to the nucleus.
Since active Src is sufficient for spontaneous migration [1] and
our data indicates that Src regulates cleavage of MUC1, we asked
whether MUC1 was functioning downstream of Src activity to
Figure 1. MUC1 is required for EGF-dependent tumor cell metastasis. (a) FG human pancreatic carcinoma cells expressing a control shRNA
or MUC1 shRNA and stimulated with or without a 15 minute treatment of EGF were inoculated on to the chorioallantoic membrane of 10 day-old
embryonated chicken eggs and assessed for spontaneous pulmonary metastasis (left) and primary tumor formation (right) after 10 days. Cells were
washed with PBS prior to inoculation to remove EGF. Metastasis quantified by Q-PCR for human Alu sequence and chicken GAPDH was normalized to
a standard curve. Each point represents a separate egg, n$6 eggs per group. Immunoblot detecting MUC1 expression (far right). P,0.0001
comparing metastasis for cells expressing control shRNA with or without EGF treatment; P=0.08 comparing metastasis for cells expressing MUC1
shRNA with or without EGF treatment; P,0.0001 comparing metastasis for cells expressing control shRNA or MUC1 shRNA with EGF treatment;
P=0.6 comparing primary tumor mass across groups. (b) Migration assays on a vitronectin (left) or a collagen (right) substrate comparing FG cells
expressing a control shRNA or MUC1 shRNA with or without a 15 minute pre-treatment of EGF. Cells were washed with PBS prior to inoculation on
Boyden chambers to remove EGF. P=0.002 comparing migration on vitronectin for cells expressing control shRNA with or without EGF treatment;
P=0.8 comparing migration on vitronectin for cells expressing MUC1 shRNA with or without EGF treatment; P=0.002 comparing migration on
vitronectin for cells expressing control shRNA or MUC1 shRNA with EGF treatment; P=0.5 comparing migration on collagen across groups. Results
are expressed as mean 6 s.e.m. of three replicates. Similar findings were observed in 3 independent experiments.
doi:10.1371/journal.pone.0036753.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36753Figure 2. Nuclear localization of MUC1 is EGF-dependent. (a) Representative images of immunofluorescence of MUC1.FL fused to GFP
(MUC1.FL.GFP; green) with or without a 15 minute pre-treatment with EGF; nuclei are counter-stained with TO-PRO-3 (blue). Schematic (left)
illustrates the MUC1.FL.GFP protein product including ectodomain (white), cytoplasmic domain (black) and GFP (hatched). Quantification of nuclear
MUC1 (bar graph) is expressed as a percentage of total detectable MUC1. Scale bar represents 10 mm. * P,0.0001 compared to unstimulated cells. (b)
Immunoblot detecting MUC1 cytoplasmic domain showing enrichment of MUC1 cytoplasmic domain with EGF treatment in the nuclear fraction from
FG cells. Fraction purity and loading were determined by immunoblotting for PARP (Nuclear, Nuc) and GAPDH (Cytoplasmic, Cyto). Line graph shows
quantification of MUC1 in each fraction by densitometry. (c) Quantitative RT-PCR of FG cells treated for 15 minutes with EGF compared to untreated
control. Peak expression changes over a 24 h period are reported. Values have been normalized to b-actin. Results are expressed as mean 6 s.e.m.
Similar findings were observed in 3 independent experiments.
doi:10.1371/journal.pone.0036753.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36753Figure 3. EGF enhances nuclear localization of MUC1 by regulating its cleavage. (a) Immunoblot detecting MUC1 cytoplasmic domain
showing increased levels of cleavage product with EGF treatment in whole-cell lysates from FG cells. (b) Representative images of
immunofluorescence of MUC1.FL and MUC1.CD fused to GFP (MUC1.FL.GFP and MUC1.CD.GFP, respectively; green); nuclei are counter-stained
with TO-PRO-3 (blue). Schematics (left) illustrate MUC1.FL.GFP and MUC1.CD.GFP protein products including ectodomain (white), cytoplasmic domain
(black) and GFP (hatched). Quantification of nuclear MUC1 (bar graph) is expressed as a percentage of total detectable MUC1. Scale bar represents
10 mm. * P,0.0001 compared to cells expressing MUC1.FL.GFP. (c) Quantitative RT-PCR of FG cells treated for 15 minutes with EGF (white) or
expressing MUC1.CD (black) compared to untreated or vector controls, respectively. For cells treated with EGF, peak expression changes over a 24 h
period are reported. Values have been normalized to b-actin. Results are expressed as mean 6 s.e.m. Similar findings were observed in 3 independent
experiments.
doi:10.1371/journal.pone.0036753.g003
EGF and Src Promote Metastasis by Cleavage of MUC1
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36753Figure 4. MUC1 cytoplasmic domain is necessary and sufficient for migration and metastasis. (a) Migration assays on a vitronectin (left)
or a collagen (right) substrate comparing FG cells co-expressing MUC1 shRNA and shRNA-resistant full-length MUC1 (MUC1.FL) or cytoplasmic
domain-deleted MUC1 (MUC1.CT3) with or without a 15 minute pre-treatment of EGF. Cells were washed with PBS prior to inoculation on Boyden
chambers to remove EGF. Schematic (top) illustration of MUC1.FL and MUC1.CT3 protein products including ectodomain (white) and cytoplasmic
domain (black). Immunoblot detecting MUC1 expression with Cell Signaling Technology anti-MUC1 clone VU4H5 (bottom). P,0.0001 comparing
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dependent migration, FG cells expressing active Src were
transfected with MUC1 siRNA or non-silencing siRNA control.
While active Src enhanced avb5-mediated migration of cells on
vitronectin as expected, knockdown of MUC1 expression with
either of two siRNAs selectively blocked Src-dependent migration
on vitronectin but had no effect on Src-independent migration on
collagen (Figure 5d). Interestingly, whereas EGF-induced
carcinoma cell migration on vitronectin is sensitive to Src
inhibition as expected [1], cell migration driven by the MUC1
cytoplasmic domain does not require Src kinase activity
(Figure 5e). These data are consistent with the hypothesis that
Src activity promotes cell migration by regulating cleavage of
MUC1.
Discussion
Metastasis is responsible for most cancer deaths. Since cross-talk
between receptor tyrosine kinases and integrins regulates the
metastatic capacity of various human cancers [3], characterization
of the molecular mechanisms resulting from this cross-talk is
essential to understanding metastasis. Here, we have identified
signaling events coordinated by EGFR and integrin avb5 that
regulate the invasive behavior of human carcinoma cells.
MUC1 expression enhances tumor cell invasion [23,26],
proliferation [33,34] and survival [35,36,37] and is thereby linked
to metastasis in several epithelial cancers, including pancreatic and
breast carcinomas [14,15]. As such, MUC1 represents a useful
diagnostic and prognostic marker in cancer patients [38], and
MUC1 vaccines targeting the ectodomain are currently being
studied in ongoing clinical trials [39,40,41]. We previously
demonstrated coordinated regulation of metastasis by EGFR
and integrin avb5 [1,7]. While integrin avb5 is unable to initiate
cell migration/invasion in the absence of growth factor stimulation
[5], stimulation of tumor cells with EGF selectively enhances the
ability of cells expressing integrin avb5 to invade on vitronectin in
vitro and metastasize in vivo [6,7]. Moreover, cell migration and
metastasis mediated by integrin avb5 requires the EGF-dependent
activation of Src, which in turn is sufficient for carcinoma cell
migration and metastasis [1]. Here, we extend our understanding
of this critical signaling pathway by identifying MUC1 as a critical
effector of EGF-dependent cell migration and metastasis mediated
by integrin avb5. Specifically, MUC1 was necessary for EGF-
induced migration and metastasis mediated by integrin avb5
(Figure 1). Furthermore, the MUC1 cytoplasmic domain was
both necessary and sufficient to promote migration and metastasis
mediated by integrin avb5( Figure 4). Significantly, it did not
impact migration mediated by b1 integrins (Figure 4). To our
knowledge, this is the first time that the MUC1 cytoplasmic
domain has been demonstrated to play a role in discrete integrin-
mediated signaling pathways leading to cell migration and
metastasis. As such, antagonists of EGFR or integrin avb5 may
provide new therapeutic options to target malignant tumors
expressing MUC1. Alternatively, it may be possible to target
MUC1 with a focused goal of suppressing its cleavage or the
function of the cytoplasmic domain.
We have previously utilized FG pancreatic carcinoma cells as
a model of the metastatic cascade that is activated downstream of
integrin avb5, and we have shown that the signaling pathways
governing this response in FG cells are representative of those
required for invasion and metastasis for a number of additional
epithelial cancer types [1,7,42]. Thus, the requirement for MUC1
in vitro and in vivo could represent a general mechanism to drive the
metastatic phenotype for carcinoma cells which are dependent
upon EGF/EGFR/Src signaling.
Although pharmacologic inhibitors of Src suppress tumor cell
metastasis in various animal models [1,43,44,45,46], the mechan-
ism(s) by which Src contributes to tumor cell metastasis at the
molecular level is not yet well-defined and new roles for Src in
metastasis are still being described [47,48]. Our study demon-
strates a requirement for MUC1 in Src-dependent migration
mediated by integrin avb5( Figure 5d). Although MUC1 has
been identified as a direct substrate of Src in vitro [11], the
significance of Src-mediated MUC1 tyrosine phosphorylation is
not completely understood but can regulate its association with
other proteins including b-catenin and HSP90 [13,16,49]. We also
observed that EGF treatment induced a Src-dependent MUC1
phosphorylation and that active Src was sufficient for MUC1
phosphorylation (data not shown). However, our findings
demonstrate an important and unexpected consequence of
interaction between MUC1 and Src: Src activity is critical for
MUC1 cleavage (Figures 5a, 5b). It is possible that Src-
dependent phosphorylation enhances the recognition of MUC1 by
a protease. Alternatively, Src may directly or indirectly promote
the activity of a protease that constitutively recognizes MUC1. A
new series of studies will be required to establish the detailed
mechanism by which Src activity enhances MUC1 cleavage.
Accumulating evidence suggests the 72-amino acid cytoplasmic
tail of MUC1 regulates a wide array of cellular processes including
proliferation, survival, and invasion by modulating signaling
pathways at the cell surface, mitochondria, and nucleus. While
the precise mechanism of MUC1 cleavage or internalization is not
well understood, previous studies have demonstrated trafficking of
MUC1 to various subcellular domains in response to receptor
tyrosine kinase activation. Importantly, EGF promotes nuclear
localization of MUC1 in association with b-catenin [28,49]. In
contrast, the EGF family member HRG promotes nucleolar
translocation of MUC1 in association with c-catenin [50]. Once in
the nucleus, MUC1 acts as a co-activator for the expression of
genes linked to tumor cell invasion and metastasis including the
EMT-promoting genes TWIST1, SNAI1 and SNAI2 [16,17,18,19].
Moreover, EGF treatment has been demonstrated to enhance
transcription of the same EMT-promoting genes [20,51]. We
observed that EGF induced nuclear localization of the MUC1
cytoplasmic domain leading to expression of genes linked to tumor
cell invasion and metastasis including TWIST1, SNAI1 and SNAI2
(Figure 2c). This was mimicked by expression of the MUC1
cytoplasmic domain (Figure 3c), suggesting that EGF promotes
migration on vitronectin for cells expressing MUC1.FL with or without EGF treatment; P=0.3 comparing migration on vitronectin for cells expressing
MUC1.CT3 with or without EGF treatment; P=0.3 comparing migration on collagen across groups. Results are expressed as mean 6 s.e.m. of three
replicates. Similar findings were observed in 3 independent experiments. (b) Migration assays on a vitronectin (left) or a collagen (right) substrate
comparing FG cells expressing vector control or MUC1 cytoplasmic domain (MUC1.CD). Schematic (top) illustration of MUC1.FL and MUC1.CD protein
products including ectodomain (white) and cytoplasmic domain (black). Immunoblot detecting MUC1 expression (far right). P=0.0003 comparing
migration on vitronectin; P=0.2 comparing migration on collagen. Results are expressed as mean 6 s.e.m. of three replicates. Similar findings were
observed in 3 independent experiments. (c) Assessment of spontaneous pulmonary metastasis (left) and primary tumor formation (right) for FG cells
expressing vector control, MUC1.CT3, or MUC1.CD in the chick CAM model. Metastasis quantified by Q-PCR for human Alu sequence and chicken
GAPDH was normalized to a standard curve. Each point represents a separate egg, n$6 eggs per group. * P,0.005.
doi:10.1371/journal.pone.0036753.g004
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metastatic gene signature.
Expression of EGFR, Src, integrin avb5, and MUC1 are
associated with the invasive and metastatic potential of various
human cancers [3,15]. Several MUC1 vaccines are currently in
phase 3 clinical trials in patients with breast or lung cancer.
Furthermore, the MUC1 intracellular domain has become the
focus of therapeutic strategies, and MUC1 peptide antagonists
have yielded promising results as anti-tumor therapies in mouse
models of breast and prostate cancer [52,53,54,55]. Given that the
Figure 5. Src activity is necessary and sufficient for MUC1 cleavage, and MUC1 is required for Src-dependent migration. (a)
Immunoblot detecting MUC1 cytoplasmic domain showing pre-treatment with a Src inhibitor (bosutinib, 500 nM) blocks EGF-dependent MUC1
cleavage in whole-cell lysates from FG cells. (b) Immunoblot detecting MUC1 cytoplasmic domain showing increased levels of cleavage product in FG
cells expressing constitutively active Src compared to vector control. (c) Immunoblot detecting MUC1 cytoplasmic domain showing enrichment of
MUC1 cytoplasmic domain in the nuclear fraction from FG cells expressing constitutively active Src compared to vector control. Fraction purity and
loading were determined by immunoblotting for PARP (Nuclear, Nuc) and GAPDH (Cytoplasmic, Cyto). (d) Migration assays on a vitronectin (left) or
a collagen (right) substrate in a Boyden chamber comparing FG cells co-expressing constitutively active Src and either a control siRNA or one of two
different MUC1 siRNAs. Immunoblot detecting MUC1 expression (far right). P,0.0001 comparing migration on vitronectin for cells expressing vector
control or active Src; P,0.0001 comparing migration on vitronectin for cells expressing control siRNA or either MUC1 siRNA; P=0.2 comparing
migration on collagen across groups. (e) Migration assays on a vitronectin (left) or a collagen (right) substrate in a Boyden chamber comparing FG
cells expressing either vector control or MUC1.CD with or without a 15 minute pre-treatment of EGF in the presence or absence of a Src inhibitor
(bosutinib, 500 nM). P=0.7 comparing migration on vitronectin for cells expressing MUC1.CD with or without Src inhibitor treatment. Similar findings
were observed in 3 independent experiments.
doi:10.1371/journal.pone.0036753.g005
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studies suggest that therapies targeting the MUC1 ectodomain on
tumor cells may provide limited clinical benefit. Importantly,
pharmacologic inhibition of Src signaling with bosutinib sup-
presses MUC1 cleavage, suggesting that targeting the pathways
responsible for MUC1 cleavage may represent a promising
alternative therapeutic approach. Therefore, therapies suppressing
MUC1 cleavage, including antagonists of EGFR and Src, might
be beneficial in controlling a wide variety of malignant tumors.
Materials and Methods
Antibodies and inhibitors
Antibodies were purchased from Abcam (GFP), BD Biosciences
(PARP), Cell Signaling Technology (MUC1 VU4H5, Src pY416),
Millipore (GAPDH, Src GD11), Santa Cruz (ERK2, HSP90),
Sigma (b-actin), and Thermo Fisher Scientific (MUC1 CT-2). The
Src inhibitor bosutinib [56] was used at 500 nM.
Cell culture
Mycoplasma-negative FG human pancreatic carcinoma cells
[57] were grown in DMEM (Life Technologies) supplemented
with 10% fetal bovine serum. For some experiments, subconfluent
cells were transfected with constitutively active Src (Y527F) in
pcDNA3.1 using the Amaxa Nucleofector I (Lonza).
Short hairpin RNA knockdown
MUC1 and GFP control lentiviral shRNA in pLKO.1
expressing system were from Open Biosystems. Lentiviruses were
produced in 293FT cells using FuGene transfection. Cells were
selected 48 h after infection with 1 mg/mL puromycin and single-
cell clones were isolated, propagated, and screened. For some
experiments, subconfluent cells were transfected with MUC1 small
interfering RNAs (Qiagen) using Lipofectamine2000 (Life Tech-
nologies), and migration assays were performed at 48 h after
transfection.
MUC1 expression
Full length and cytoplasmic domain-deleted MUC1 were
generously provided by Michael Hollingsworth [23]. The
39UTR was removed from these constructs before transfection
into cells. The 72 amino acid MUC1 cytoplasmic domain was
cloned by PCR and sequenced. MUC1 knockdown cells were
transfected with rescue constructs in pcDNA3.1 using Lipofecta-
mine2000 (Life Technologies) and serum starved overnight, and
migration assays were performed at 48 h after transfection. For
some experiments, the stop codon was removed by site-directed
mutagenesis (Agilent Technologies) and the construct was cloned
into pGFP (Clontech Laboratories) and then pCDH lentivirus
expressing system (System Biosciences). Cells were selected by flow
cytometry.
Protein analysis
Cells were serum starved overnight, pretreated with inhibitors,
and stimulated with EGF (50 ng/mL) (Millipore). Immunoblotting
and immunofluorescence was performed as previously described
[57,58,59]. Subcellular fraction was performed as previously
described [60]. Images were captured using a TE200E Nikon
C1S spectral confocal microscope and analyzed with MetaMorph
software (Molecular Devices). Flow cytometry was performed at
the UCSD Cancer Center Shared Resource.
RNA isolation and RT-PCR assays
RNA isolation was performed with Trizol (Life Technologies)
according to the manufacturer’s instructions. cDNA was generated
using the Superscript III First-strand Synthesis Kit (Life Technol-
ogies). Reactions containing 200 ng cDNA were prepared in
QuantiTect SYBR Green Master Mix (Qiagen) and subjected to
quantitative RT-PCR analysis using a Smart Cycler (Cepheid).
Values were obtained for the threshold cycle (Ct) for each gene
and normalized to b-actin. Values are provided as fold change.
For some experiments, cells were treated with EGF (50 ng/mL)
for 1, 3, 8, or 24 h before RNA extraction.
Cell migration and chick embryo metastasis
Migration assays were performed as previously described [57].
Chick embryo metastasis assays were performed as previously
described [1]. Briefly, FG cells were stimulated with a 15 minute
treatment of EGF or vehicle in vitro and then implanted on the
chorioallantoic membrane of 10 day-old chick embryos. After 10
days, primary tumors were weighed and spontaneous lung
metastasis was assessed by Q-PCR.
Statistical analysis
Data presented represent mean 6 s.e.m. Statistical analyses
were performed with Excel (Microsoft) or Prism (GraphPad).
Statistical differences for one factor between two groups or more
than two groups were determined with an unpaired Student’s t-test
or an analysis of variance (ANOVA) with post-hoc testing,
respectively. Statistical significance was defined as P,0.05.
Supporting Information
Figure S1 MUC1 is required for EGF-dependent gene
transcription. Quantitative RT-PCR of FG cells not expressing
(white) or expressing (black) MUC1 shRNA and treated for
15 minutes with EGF compared to untreated controls. Peak
expression changes over a 24 h period are reported. Values have
been normalized to b-actin.
(PDF)
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